TITLE

Pancreatic cancer: current management and treatment strategies

AUTHOR(S)
Gall, Tamara M. H.; Tsakok, Maria; Wasan, Harpreet; Jiao, Long R.
PUB. DATE
October 2015
SOURCE
Postgraduate Medical Journal;Oct2015, Vol. 91 Issue 1080, p601
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
The 5-year survival of patients with pancreatic cancer is poor and, despite oncological advances over the past two decades, has not significantly improved. However, there have been several surgical and oncological advances which have improved morbidity and mortality in surgery and more efficacious chemotherapy regimens, resulting in a better patient experience and an increase in survival by a number of months. Most patients have a tumour at the head of the pancreas and those with resectable disease undergo a pancreaticoduodenectomy, which can be performed laparoscopically. Those who have a pancreatic resection have an increased survival in comparison with those receiving oncological treatment only; however, only a quarter of patients have resectable disease at diagnosis. Some centres are now performing venous resections and/or arterial resections in order to increase the number of patients eligible for curative surgery. Innovative techniques using ablation technologies to downstage tumours for resection are also being investigated. After surgery, all patients should be offered adjuvant gemcitabine-based chemotherapy. Those with locally advanced tumours not suitable for surgery should be offered FOLFIRINOX chemotherapy, after which the tumour may be suitable for surgical resection. The use of radiotherapy in this group of patients is controversial but offered by a few centres. Patients with metastatic disease at diagnosis should also be offered FOLFIRINOX chemotherapy, which can improve survival by a few months. As our knowledge of the tumour biology of pancreatic cancer progresses, a number of new agents targeting specific genes and proteins are under investigation and there is hope that median survival will continue to improve over the next decade.
ACCESSION #
110245590

 

Related Articles

  • Management strategies in pancreatic cancer. Campen, Christopher J.; Dragovich, Tomislav; Baker, Amanda F. // American Journal of Health-System Pharmacy;4/1/2011, Vol. 68 Issue 7, p573 

    Purpose. Current first-line and adjuvant chemotherapeutic strategies for management of patients with pancreatic cancer are reviewed. Summary. Pancreatic adenocarcinoma is the 10th most prevalent cancer and the fourth most common cause of cancer deaths in the United States. More than 80% of...

  • Nursing Implications of Chemotherapy Agents and Their Associated Side Effects in Patients With Pancreatic Cancer. Hronek, Jan W.; Lehner Reed, Maureen // Clinical Journal of Oncology Nursing;Dec2015, Vol. 19 Issue 6, p751 

    Background: Survival for patients with advanced (locally advanced unresectable and metastatic disease) pancreatic cancer is very poor; however, several advances in treatment have been made during the past several years. Gemcitabine (Gemzar®)-based regimens, FOLFIRINOX, and nab-paclitaxel...

  • Emerging treatments for advanced pancreatic cancer: clinical potential of albumin-bound paclitaxel. Fontana, Elisa; Sclafani, Francesco; Cunningham, David // Gastrointestinal Cancer: Targets & Therapy;2014, Vol. 4, p89 

    The management of pancreatic cancer has historically represented a major challenge for oncologists. The inherent aggressiveness of this tumor and the fibrotic features of the surrounding stromal tissue have significantly limited the impact of standard chemotherapy. Moreover, the paucity of...

  • Inflammation to cancer: The molecular biology in the pancreas (Review). SUNBIN LING; TINGTING FENG; KAIQI JIA; YU TIAN; YAN LI // Oncology Letters;2014, Vol. 7 Issue 6, p1747 

    Inflammatory responses are known to be correlated with cancer initiation and progression, and exploration of the route from inflammation to cancer makes a great contribution in elucidating the mechanisms underlying cancer development. Pancreatic cancer (PC) is a lethal disease with a low...

  • Pancreatic cancer cachexia: a review of mechanisms and therapeutics. Tan, Carlyn R.; Yaffee, Patrick M.; Jamil, Laith H.; Lo, Simon K.; Nissen, Nicholas; Pandol, Stephen J.; Tuli, Richard; Hendifar, Andrew E. // Frontiers in Physiology;Mar2014, Vol. 5, p1 

    Over the last decade, we have gained new insight into the pathophysiology of cachexia associated with pancreatic cancer. Unfortunately, its treatment is complex and remains a challenge. Pancreatic cancer cachexia is a multifactorial syndrome characterized by uncompensated adipose tissue and...

  • Gemcitabine Resistance is Associated with Epithelial-Mesenchymal Transition and Induction of HIF-1α in Pancreatic Cancer Cells. Rui Wang; Long Cheng; Jun Xia; Zishu Wang; Qiong Wu; Zhiwei Wang // Current Cancer Drug Targets;May2014, Vol. 14 Issue 4, p407 

    Pancreatic cancer is one of the highly aggressive malignant diseases worldwide. To achieve better treatment outcome of pancreatic cancer, in the current study we explore the underlying molecular mechanism of drug resistance in pancreatic cancer cells. We found that resistance to gemcitabine is...

  • ERRATUM.  // Current Clinical Pharmacology;Sep2009, Vol. 4 Issue 3, p239 

    A correction to the article "Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer" that was published in a 2009 issue is presented.

  • Pancreatic Cancer: Current and Emerging Trends in Detection and Treatment. Rochman, Hazel // Booklist;9/15/2009, Vol. 106 Issue 2, p56 

    Reviews the book "Pancreatic Cancer: Current and Emerging Trends in Detection and Treatment," by Amy Sterling Casil.

  • Pancreatic enzymes for cancer cure.  // Patient Care;9/15/2001, Vol. 35 Issue 17, p68 

    Focuses on the use of pancreatic enzymes for the treatment of pancreatic cancer. Alternative treatment for pancreatic cancer.

  • 胰腺癌分子靶向治疗的研究进展. 许莹; 戴树龙 // Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi;Oct2016, Vol. 32 Issue 10, p2026 

    Pancreatic cancer remains one of the malignant tumors with the worst prognosis, and its incidence is associated with Western diet, smoking, drinking, obesity, chronic pancreatitis, and a family history of pancreatic cancer. Currently, the treatment of pancreatic cancer focuses on surgery and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics